基于2型炎症生物标志物对哮喘急性发作口服糖皮质激素反应的表型分型研究(PRISMA)
该纵向观察性研究纳入53例哮喘急性发作患者,在7天口服糖皮质激素(OCS)疗程前后进行评估,按血嗜酸性粒细胞计数(BEC)和呼出气一氧化氮(FENO)联合分层为T2-Low/Low、T2-Mid和T2-High/High三组。主要结局为支气管舒张后FEV1变化,结果显示FEV1改善随BEC-FENO联合升高而增加(交互作用P=0.007),T2-High/High组改善最显著(0.390±0.512 L,趋势P<0.0001),而T2-Low/Low组FEV1变化无统计学意义(0.017±0.153 L)。
要点
- OCS后支气管舒张后FEV1改善仅见于T2-High/High表型,T2-Low/Low表型无显著改善。
- BEC-FENO联合分层可预测OCS后FEV1改善,而症状和基线FEV1无预测价值。
- 各组OCS相关不良事件发生率相似,62%患者报告至少1项事件。
核心结论
- OCS后客观肺功能改善仅限于T2-High/High哮喘急性发作事件。
- BEC-FENO联合分层可识别对OCS有不同治疗轨迹的急性哮喘表型,而OCS相关不良事件在各组分布均匀。
研究设计与样本
- 纵向观察性研究,纳入53例哮喘急性发作患者,在7天OCS疗程前后进行评估。
- 按BEC-FENO三组分类:T2-Low/Low(BEC<0.15×10^9 cells·L-1且FENO<25 ppb)、T2-High/High(BEC≥0.30×10^9 cells·L-1且FENO≥35 ppb)、T2-Mid(不满足Low/Low或High/High标准)。
- 主要结局为支气管舒张后FEV1变化;关键次要结局为ACQ-5评分变化;探索性结局包括OCS相关不良事件。
主要发现
- 53例中T2-Low/Low 16例(30%)、T2-Mid 27例(51%)、T2-High/High 10例(19%)。
- 支气管舒张后FEV1变化随BEC-FENO联合升高而增加(交互作用P=0.007),T2-High/High组改善最显著(0.390±0.512 L,趋势P<0.0001);T2-Low/Low组FEV1变化无统计学意义(0.017±0.153 L)。
- 单变量和多变量分析中,仅BEC-FENO有序分层预测后续支气管舒张后FEV1改善,症状和FEV1均无预测价值。
- 所有患者ACQ-5评分均改善,T2-High/High组数值上改善最大(-1.58±0.60,趋势P=0.08)。
- 各组OCS相关不良事件相似,33例(62%)报告至少1项事件。
关键数值与推荐
- T2-Low/Low定义:BEC<0.15×10^9 cells·L-1且FENO<25 ppb。
- T2-High/High定义:BEC≥0.30×10^9 cells·L-1且FENO≥35 ppb。
- T2-Mid定义:不满足T2-Low/Low或T2-High/High标准。
- OCS疗程为7天。
临床怎么用
- 对哮喘急性发作患者,可结合BEC和FENO联合分层识别可能从OCS获得肺功能获益的T2-High/High表型。
- T2-Low/Low表型急性发作患者OCS后FEV1无显著改善,需权衡OCS获益与不良事件风险。
- OCS相关不良事件在各表型组分布均匀,不应仅凭T2表型判断不良事件风险。
局限性
- 样本量较小(53例),T2-High/High组仅10例。
- 为观察性研究,未设对照组,不能确立因果关系。
- ACQ-5改善的趋势P=0.08未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma attacks are heterogeneous. It is not known whether the response to oral corticosteroids (OCS) in acute asthma varies according to type 2 (T2) inflammatory biomarkers, blood eosinophil count (BEC) and fractional exhaled nitric oxide (F ENO). We aimed to explore the relationship between T2 biomarkers and response to OCS in acute asthma. METHODS: We conducted a longitudinal observational study of people experiencing an asthma attack evaluated before and after a 7-day OCS course. The primary outcome was post-bronchodilator change in forced expiratory volume in 1 s (FEV1) according to ordinal BEC-F ENO three-group categories (T2-Low/Low: BEC <0.15×109 cells·L-1 and F ENO <25 ppb; T2-High/High: BEC ≥0.30×109 cells·L-1 and F ENO ≥35 ppb; T2-Mid: not meeting Low/Low or High/High criteria). A key secondary outcome was the change in Asthma Control Questionnaire-5 score. Exploratory outcomes included OCS-attributable adverse events. RESULTS: 53 people were enrolled, with 16 (30%) T2-Low/Low, 27 (51%) T2-Mid and 10 (19%) T2-High/High asthma attacks. Post-bronchodilator FEV1 changes increased with combined BEC-F ENO elevation (p for interaction=0.007), peaking in the T2-High/High phenotype (0.390±0.512 L, p for trend<0.0001). Conversely, T2-Low/Low attacks showed nonsignificant FEV1 changes (0.017±0.153 L). In univariable and multivariable analyses, only ordinal BEC-F ENO stratification, not symptoms nor FEV1, predicted subsequent post-bronchodilator FEV1 improvement. All patients had improved Asthma Control Questionnaire-5 score, numerically peaking in the T2-High/High phenotype (-1.58±0.60, p for trend=0.08). All groups experienced similar OCS-attributable adverse events, with 33 patients (62%) reporting at least one event. CONCLUSIONS: We found that objective improvement following OCS is confined to T2-High events. As in chronic asthma, greater T2 burden identifies a distinct clinical and therapeutic trajectory, whereas OCS‑related adverse events are uniformly distributed.
引用
- Celis-Preciado C, Leclerc S, Duval M, et al. Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA). Eur Respir J. 2025. PMID: 39947666. doi:10.1183/13993003.02391-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。